Evidence map›Paper›PMID 38159060›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Significance of a positive tau PET scan with a negative amyloid PET scan.

Carling G Robinson, Jeyeon Lee, Paul H Min, Scott A Przybelski, Keith A Josephs, David T Jones, Jonathan Graff-Radford, Bradley F Boeve, David S Knopman, Clifford R Jack and 4 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Article
  3. Establishing tau-PET cut-points for cognitive diagnosis withImaging neuroscience (Cambridge, Mass.) · 2025
    Article
  4. Investigating the feasibility ofAlzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Observational
  5. Review
  6. Significance of a positive tau PET scan with a negative amyloid PET scan.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Carling G RobinsonDepartments of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jeyeon LeeCollege of Medicine, Hanyang University, Seoul, South Korea.
Paul H MinDepartments of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Scott A PrzybelskiDepartments of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Keith A JosephsDepartments of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
David T JonesDepartments of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartments of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Bradley F BoeveDepartments of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
David S KnopmanDepartments of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R JackDepartments of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Ronald C PetersenDepartments of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Mary M MachuldaDepartments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Julie A FieldsDepartments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Val J LoweDepartments of Radiology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5612-1667

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Protecting the Confidentiality of Participants in Studies of Alzheimer's Disease and Related Dementias by Replacing Face Imagery in MRIR01AG068206 · NIA · MAYO CLINIC ROCHESTER · PI SCHWARZ, CHRISTOPHER GEORGE · 2021 to 2024
$3.2M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG056366NIA NIH HHS R01 AG068206NIA NIH HHS R01 AG073282NIA NIH HHS R33 AG058738NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NIA NIH HHS U19 AG063911NIH HHS P30 AG62677NIH HHS P50 AG016574NIH HHS R01 AG034676NIH HHS R01 AG041851NIH HHS R01 AG056366NIH HHS R01 AG068206NIH HHS R01 AG073282NIH HHS R01 NS097495NIH HHS R37 AG011378NIH HHS U01 AG006786NIH HHS U01 NS100620NIH HHS U19 AG063911NINDS NIH HHS R01 NS097495NINDS NIH HHS U01 NS100620
6 · The paper itself

Abstract

introductionThe implications of positive tau positron emission tomography (T) with negative beta amyloid positron emission tomography (A) are not well understood. We investigated cognitive performance in participants who were T+ but A-.

methodsWe evaluated 98 participants from the Mayo Clinic who were T+ and A-. Participants were matched 2:1 to A- and T- cognitively unimpaired (CU) controls. Cognitive test scores were compared between different groups.

resultsThe A-T+ group demonstrated lower performance than the A-T- group on the Mini-Mental Status Exam (MMSE) (p < 0.001), Wechsler Memory Scale-Revised Logical Memory I (p < 0.001) and Logical Memory II (p < 0.001), Auditory Verbal Learning Test (AVLT) delayed recall (p = 0.004), category fluency (animals p = 0.005; vegetables p = 0.021), Trail Making Test A and B (p < 0.001), and others. There were no significant differences in demographic features or apolipoprotein E (APOE) e4 genotype between CU A-T+ and CI A-T+. DISCUSSION: A-T+ participants show an association with lower cognitive performance.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloidAmyloid beta-PeptidesBrainHumansPositron-Emission Tomographytau ProteinsAmyloidAmyloid beta-Peptidestau ProteinsAlzheimer's diseaseamyloid PETcognitionFTP-PETtautauopathies

Identifiers

PMID38159060
PMCPMC10947949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.